PROGEN Biotechnik Overview

  • Year Founded
  • 1983

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 49

Employees

  • Latest Deal Type
  • Series B

  • Financing Rounds
  • 3

  • Investments
  • 1

PROGEN Biotechnik General Information

Description

Manufacturer and supplier of premium antibodies intended to serve the global life science research community. The company specializes in the development of antibodies, in vitro diagnostics and research reagents, thereby enabling scientists to be provided with products and ultimately deliver improved antibodies and exclusive adeno-associated viruses (AAV) products.

Contact Information

Website
www.progen.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Parent Company
R-Biopharm
Primary Office
  • Maaßstraße 30
  • 69123 Heidelberg
  • Germany
+49 06221 00000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PROGEN Biotechnik Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PROGEN Biotechnik‘s full profile, request access.

Request a free trial

PROGEN Biotechnik Patents

  • 62

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 000

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

PROGEN Biotechnik Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-102006010958-A1 Method for carrying out a reaction for the amplification of a nucleic acid Inactive 06-Mar-2006 00000000
EP-1993730-A1 Method of carrying out a reaction for replicating a nucleic acid Inactive 06-Mar-2006 00000000
DE-102006010959-A1 Apparatus for detecting biochemical target molecules, designed to perform all of cell lysis, purification, amplification and detection in a single liquid flow system Inactive 06-Mar-2006 000000000000
DE-202006020469-U1 Device for detecting biochemical target molecules Inactive 06-Mar-2006 000000000000
DE-102005008224-B3 Apparatus for automatically activating microfluid device, for carrying out biochemical purifications and assays, having activator controlled on the basis of measurements of exerted force Inactive 23-Feb-2005 B01L3/0293
To view PROGEN Biotechnik’s complete patent history, request access »

PROGEN Biotechnik Executive Team (6)

Name Title Board Seat Contact Info
Katja Betts Co-Chief Executive Officer
Maik Lander Co-Chief Executive Officer
You’re viewing 2 of 6 executive team members. Get the full list »

PROGEN Biotechnik Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PROGEN Biotechnik Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore PROGEN Biotechnik‘s full profile, request access.

Request a free trial

PROGEN Biotechnik Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
MICROBIONIX 01-Jan-2011 0000000000 Laboratory Services (Healthcare)
To view PROGEN Biotechnik’s complete acquisitions history, request access »